Semaglutide 2.4 mg injection demonstrated significant weight loss versus placebo when added to intensive behavioral therapy ...Middle East

PR Newswire - News
Semaglutide 2.4 mg injection demonstrated significant weight loss versus placebo when added to intensive behavioral therapy
PLAINSBORO, N.J., Nov. 5, 2020 /PRNewswire/ -- Results of a phase 3a trial showed that the investigational drug semaglutide 2.4 mg once-weekly subcutaneous (sc) as an adjunct to intensive behavioral therapy (IBT) demonstrated significantly more body weight loss compared to placebo plus...

Read More Details
Finally We wish PressBee provided you with enough information of ( Semaglutide 2.4 mg injection demonstrated significant weight loss versus placebo when added to intensive behavioral therapy )

Apple Storegoogle play

Also on site :

Most viewed in News